Literature DB >> 33585102

Radiotherapy Planning System to Measure Tumor Doubling Time in Cervical Cancer.

Hiromasa Kurosaki1, Nobuko Utsumi1, Kosei Miura1,2.   

Abstract

Tumor doubling time is an important clinical parameter, but it is rarely reported in cervical cancer. We encountered a case in which the tumor doubling time could be measured using a radiotherapy planning device. A woman in her 40s was diagnosed with cervical cancer stage IB1 (squamous cell carcinoma) and refused treatment. One year and five months later, definitive radiation therapy was administered. Magnetic resonance imaging was performed five times before the start of treatment. When the tumor volume was measured using the radiotherapy planning system - RayStation🄬 (RaySearch Laboratories, Stockholm, Sweden) on the T2 sagittal image, the tumor doubling time was 76 days, and the tumor volume had increased exponentially.
Copyright © 2021, Kurosaki et al.

Entities:  

Keywords:  cervical cancer; radiotherapy planning system; tumor doubling time

Year:  2021        PMID: 33585102      PMCID: PMC7872496          DOI: 10.7759/cureus.12612

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  13 in total

1.  A biomathematical approach to clinical tumor growth.

Authors:  M SCHWARTZ
Journal:  Cancer       Date:  1961 Nov-Dec       Impact factor: 6.860

2.  Observations on growth rates of human tumors.

Authors:  V P COLLINS; R K LOEFFLER; H TIVEY
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1956-11

3.  Tumor doubling time predicts response to sorafenib in radioactive iodine-refractory differentiated thyroid cancer.

Authors:  Min Joo Kim; Seok-Mo Kim; Eun Kyung Lee; Yul Hwangbo; You Jin Lee; Sun Wook Cho; Do Joon Park; Yumi Lee; Young Joo Park
Journal:  Endocr J       Date:  2019-04-19       Impact factor: 2.349

4.  Pretreatment proliferation parameters do not add predictive power to clinical factors in cervical cancer treated with definitive radiation therapy.

Authors:  Richard W Tsang; Stephen Juvet; Melania Pintilie; Richard P Hill; C Shun Wong; Michael Milosevic; William Chapman; Wilfred Levin; Lee A Manchul; Anthony W Fykes
Journal:  Clin Cancer Res       Date:  2003-10-01       Impact factor: 12.531

5.  Relationship between doubling time of liver metastases from colorectal carcinoma and residual primary cancer.

Authors:  K Nomura; S Miyagawa; H Harada; H Kitamura; H Seki; R Shimada; A Kobayashi; T Noike; S Kawasaki
Journal:  Dig Surg       Date:  1998       Impact factor: 2.588

6.  Impact of Surgical Resection on Metachronous Metastases of Colorectal Cancer According to Tumor Doubling Time.

Authors:  Hiroaki Miyake; Koji Murono; Kazushige Kawai; Hiroaki Nozawa; Harufumi Maki; Kiyoshi Hasegawa; Jun Nakajima; Soichiro Ishihara
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

7.  Doubling time of lung cancer determined using three-dimensional volumetric software: comparison of squamous cell carcinoma and adenocarcinoma.

Authors:  Osamu Honda; Takeshi Johkoh; Junko Sekiguchi; Noriyuki Tomiyama; Naoki Mihara; Hiromitsu Sumikawa; Atsuo Inoue; Masahiro Yanagawa; Tadahisa Daimon; Meinoshin Okumura; Hironobu Nakamura
Journal:  Lung Cancer       Date:  2009-02-28       Impact factor: 5.705

8.  Influence of overall treatment time and radiobiological parameters on biologically effective doses in cervical cancer patients treated with radiation therapy alone.

Authors:  Anna Gasinska; Jack F Fowler; Bengt K Lind; Krzysztof Urbanski
Journal:  Acta Oncol       Date:  2004       Impact factor: 4.089

Review 9.  The growth rate of human tumours.

Authors:  G G Steel; L F Lamerton
Journal:  Br J Cancer       Date:  1966-03       Impact factor: 7.640

10.  Solid component tumor doubling time is a prognostic factor in non-small cell lung cancer patients.

Authors:  Kentaro Miura; Kazutoshi Hamanaka; Tomonobu Koizumi; Satoshi Kawakami; Nobutaka Kobayashi; Ken-Ichi Ito
Journal:  J Cardiothorac Surg       Date:  2019-03-12       Impact factor: 1.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.